ASCO Publishes Abstracts for Alnylam, Silence Cancer Drugs
May 26, 2011
ASCO Publishes Abstracts for Alnylam, Silence Cancer Drugs
The abstracts provided quick glimpses of new phase I data on the companies' respective siRNA-based cancer drugs, showing that both are well-tolerated and providing hints about their possible efficacy.
Full-text access for premium subscribers only.
Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.
New to GenomeWeb? Register here quickly.
Related Stories
- Silence Presents Phase I Data on siRNA-based Cancer Drug at ASCO, Touts Safety of Delivery System
June 9, 2011 / Gene Silencing News - Alnylam Presents Phase I Data at ASCO Showing Liver Cancer Drug Well Tolerated
June 9, 2011 / Gene Silencing News - Silence Plans $28.6M Stock Sale to Fund Expansion of Staff, Pipeline
April 11, 2013 / Gene Silencing News - After Losing Another CEO, Silence Management Aims to Fill in Corporate Gaps
March 21, 2013 / Gene Silencing News - Tekmira Provides Pipeline Update, Eyes Agricultural Market
February 14, 2013 / Gene Silencing News